SS Innovations International Files 8-K

Ticker: SSII · Form: 8-K · Filed: Jun 11, 2024 · CIK: 1676163

Sentiment: neutral

Topics: 8-K, corporate-filing, name-change

TL;DR

SS Innovations (formerly AVRA Medical Robotics) filed an 8-K on 6/11/24. Standard reporting.

AI Summary

SS Innovations International, Inc. filed an 8-K on June 11, 2024, reporting other events and financial statements. The company, formerly known as AVRA Medical Robotics, Inc. since June 1, 2016, is incorporated in Florida and headquartered in Fort Lauderdale.

Why It Matters

This filing indicates routine corporate reporting, including financial statements and other events, which provides transparency to investors about the company's current status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not contain information about significant financial changes, acquisitions, or legal issues.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for SS Innovations International, Inc.?

The filing reports 'Other Events' and 'Financial Statements and Exhibits' as of June 11, 2024.

When did SS Innovations International, Inc. change its name?

The company's former name was AVRA Medical Robotics, Inc., and the date of the name change was June 1, 2016.

Where is SS Innovations International, Inc. headquartered?

The company's principal executive offices are located at 1600 SE 15th Street, #512, Fort Lauderdale, Florida 33316.

What is the company's state of incorporation?

SS Innovations International, Inc. is incorporated in Florida.

What is the SIC code associated with SS Innovations International, Inc.?

The Standard Industrial Classification code is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.

Filing Stats: 473 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-06-11 08:30:34

Filing Documents

01 Other Events

Item 8.01 Other Events. On June 11, 2024, we issued a press release announcing that the Company's SSi Mantra Surgical Robotic System has received regulatory approval from the Indonesian Ministry of Health for clinical use in the Republic of Indonesia. A copy of the press release is included as Exhibit 99.1 to this Report.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated June 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 11, 2024 SS INNOVATIONS INTERNATIONAL, INC. By: /s/ Sudhir Srivastava Sudhir Srivastava, M.D. Chairman and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing